Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 8/20 | 0.71 |
| ▸ | JAK2 | O60674 | 6/20 | 0.71 |
| ▸ | JAK1 | P23458 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.65 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | SMO | Q99835 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168022 | 0.89 | TYK2 (0.58) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL3791414 | 0.89 | SMO (0.61) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL2845491 | 0.88 | F2R (0.63) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL30230787 | 0.88 | TYK2 (0.75) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL9884060 | 0.88 | TYK2 (0.75) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL14991989 | 0.88 | JAK1 (0.75) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL28448935 | 0.86 | TYK2 (0.55) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL7605864 | 0.85 | KMT2A (0.61) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL29493359 | 0.85 | JAK2 (0.54) | TYK2JAK2JAK1CYP3A4TAS1R3 | |
| SCHEMBL4152879 | 0.85 | PTPRC (0.61) | TYK2JAK2JAK1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| CN-1878466-A | Biphenyl derivative or salt thereof, pest control agent containing the same as active ingredient | ISHIHARA SANGYO KAISHA (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-6685617-B1 | 4-(((-1-CARBOXY-2-(4-((2,6-DICHLOROBENZOYL)AMINE)PHENYL)ETHYL) AMINO)CARBONYL)-3-OXO-3-THIAZOLIDINEBUTANOIC ACID, USED AS ANTAGONISTS FOR CELLULAR ADHESION MOLECULES, AND ADMINISTERED AS ANTIINFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-02-03 | — | — | US | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5047573-A | Process for the production of peptides using diacylamines | BRADACZEK HANS (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0259396-B1 | PROCESS FOR PEPTIDE PRODUCTION | BRADACZEK, Hans (DE) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | TYK2 60/4885JAK2 1438/4885JAK1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.